Author/Authors :
Poojar, Sridhar Kidwai Memorial Institute of Oncology - Bangalore - India , Loni, Rahul Kidwai Memorial Institute of Oncology - Bangalore - India , Raj H K, Krishna Kidwai Memorial Institute of Oncology - Bangalore - India , Naveen, Thimmaiah Kidwai Memorial Institute of Oncology - Bangalore - India , Lokesh, V Kidwai Memorial Institute of Oncology - Bangalore - India
Abstract :
Background: Most common intracranial tumor in adults is brain metastasis. Different fractionation schedules used for whole
brain radiation therapy are 20 gray/5 Fr, 30 gray/10 Fr, and 40 gray/20 Fr, which in four weeks have shown equivalent response rate,
period of improvement, palliative effect, time to disease progression, and survival. However, there is lacking literature on the effect
of different fractionation schedules of radiation therapy on memory function.
Objectives: Hence,weevaluatedmemory function intwodifferent fractionation schedules of wholebrain radiation therapy(WBRT)
in patients with brain metastases.
Methods: Atotal of 20patients,whowerehistologically proven primaryandrecently diagnosed brain metastases, with aRPAclass of
I/II, and satisfying eligibility criteria were taken into this study. Patients were randomly assigned to whole brain radiation therapy of
40 gray in 20 fractions (group A) and 30 gray in 10 fractions (group B) with concurrent Temozolomide. Memory function assessment
was done using P.G.I. Memory scale before, during, and after the treatment, as well as at three months and six months of follow-up.
Two groups were compared for with appropriate statistical tests.
Results: Patients in group A showed improvement in five domains of memory function (attention and concentration, remote and
recentmemory, mental balance and verbal retention for similar pair) during radiation therapy, compared to group B patients. However,
deterioration of memory function was noted in both groups at 3- and 6-months post chemoradiation therapy.
Conclusions: Fourty Gy in 20 fractions given over four weeks with concurrent TMZ 75 mg/m2 is a better and preferable treatment
option for patients with brain metastasis with respect to memory function.